망막혈관종성증식 환자에서 유리체강내 항혈관내피세포성장인자 주입술의 12개월 임상결과 = Twelve-Month Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the 12-month outcomes of anti-vascular endothelial growth factor (VEGF) treatment for patients with retinal angiomatous proliferation (RAP). Methods: Retrospective review of medical records was performed for 33 patients (33 eyes) who were diagnosed with RAP. All patients were initially treated with three consecutive intravitreal anti-VEGF injections after diagnosis. Additional treatment was performed when the recurrence of exudation was noted. The best-corrected visual acuity (BCVA) was measured before the first injection and at 3, 6, and 12 months after the first injection. The value measured before the treatment was compared with those measured after treatment. Results: The patients received an average of 4.2 ± 1.7 intravitreal anti-VEGF injections during the 12-month follow-up period. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and at 3, 6, and 12 months after the first injections were 0.76 ± 0.49, 0.55 ± 0.35, 0.67 ± 0.41, and 0.70 ± 0.50, respectively. BCVA was significantly improved at 3 and 6 months (p < 0.001 and p = 0.037) compared to that measured before the first injection. However, there was no significant difference between BCVA before the first injection and 12 months after the first injection (p = 0.590). At 12 months of follow-up, 29 eyes (87.9%) showed stable (

참고문헌 (Reference)

1 조윤정, "출혈우세병변이 동반된 연령관련 황반변성 환자에서의 유리체강 내 라니비주맙 주입술의 효과" 대한안과학회 52 (52): 838-845, 2011

2 변석호, "연령연관황반변성에서 망막혈관종성증식과 동반된 망막색소상피 박리의 임상양상과 일차적인 광역학치료의 결과" 대한안과학회 47 (47): 1410-1416, 2006

3 강승범, "연령관련황반변성에 동반된 맥락막신생혈관의 유리체강내 라니비주맙 주입술 임상결과" 대한안과학회 50 (50): 725-730, 2009

4 김용환, "나이관련황반변성에 의한 맥락막혈관신생에서 유리체내 베바시주맙 주입술의 장기효과" 대한안과학회 49 (49): 1935-1940, 2008

5 Hufendiek K, "Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation" 32 : 259-268, 2012

6 Holladay JT, "Visual acuity measurements" 30 : 287-290, 2004

7 Bottoni F, "Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation" 123 : 1644-1650, 2005

8 Rauch R, "Time to first treatment: the significance of early treatment of exudative age-related macular degeneration" 32 : 1260-1264, 2012

9 Massacesi AL, "The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization" 246 : 89-92, 2008

10 Liu Y, "Subtype lesions of neovascular age-related macular degeneration in Chinese patients" 245 : 1441-1445, 2007

11 Yannuzzi LA, "Retinal angiomatous proliferation in age-related macular degeneration" 21 : 416-434, 2001

12 Jae Hoon Kang, "Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection" 대한안과학회 21 (21): 213-215, 2007

13 Cohen SY, "Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting" 148 : 409-413, 2009

14 Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration" 355 : 1432-1444, 2006

15 Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration" 355 : 1419-1431, 2006

16 Chang MA, "Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration" 30 : 1171-1176, 2010

17 Oliver-Fernandez A, "Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration" 40 : 313-319, 2005

18 Riusala AM, "Predictors of structural findings in old disciform lesions" 138 : 245-253, 2004

19 Gross NE, "Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation" 25 : 713-718, 2005

20 Avery RL, "Natural history of subfoveal subretinal hemorrhage in agerelated macular degeneration" 16 : 183-189, 1996

21 Shienbaum G, "Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti–vascular endothelial growth factor monotherapy" 155 : 1009-1013, 2013

22 Konstantinidis L, "Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP)" 247 : 1165-1171, 2009

23 Parodi MB, "Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation" 91 : 267-273, 2013

24 Spaide RF, "Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration" 26 : 383-390, 2006

25 Costagliola C, "Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation" 144 : 449-451, 2007

26 Ghazi NG, "Intravitreal bevacizumab (Avastin) treatment of retinal angiomatous proliferation" 28 : 689-695, 2008

27 Bennett SR, "Factors prognostic of visual outcome in patients with subretinal hemorrhage" 109 : 33-37, 1990

28 Arias L, "Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss" 23 : 326-333, 2009

29 Lee MY, "Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients:twelve-month results" 31 : 65-73, 2011

30 Maruko I, "Clinical characteristics of exudative age-related macular degeneration in Japanese patients" 144 : 15-22, 2007

31 이필영, "1단계 망막혈관종성증식의 치료" 대한안과학회 49 (49): 442-449, 2008